Welcome to our dedicated page for Regen Biopharma news (Ticker: RGBPP), a resource for investors and traders seeking the latest updates and insights on Regen Biopharma stock.
Regen BioPharma, Inc. reports biotechnology developments tied to its OTC-traded securities, including RGBPP. Company news centers on HemaXellerate, an autologous mesenchymal stem cell product designed to stimulate bone marrow activity and restore hematopoietic function, with an initial focus on aplastic anemia and potential application in chemotherapy-induced bone marrow suppression.
Recurring updates also cover FDA-related development activity, clearance to initiate a Phase I clinical trial for HemaXellerate, orphan-drug strategy for rare-disease treatment, and presentations on the company’s scientific programs. Regen BioPharma describes a broader immunology and immunotherapy pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics, small molecule drugs, and programs for cancer and autoimmune disorders.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.